Does Anthem (Elevance Health) Cover Low-Dose Naltrexone?
Anthem (Elevance Health) coverage policy for low-dose naltrexone (LDN): prior authorization criteria, formulary tier, step therapy requirements, appeal process, and cost-saving alternatives.
Low Dose Naltrexone
67 source-based articles maintained by the HealthRX.com Editorial Team.
67articles
4topic areas covered
May 25, 2026latest review
Low Dose Naltrexone library
Showing 60 of 67 clinical reviews.
Does Cigna Cover Low-Dose Naltrexone?
A clinical guide to Cigna coverage, prior authorization, step therapy, formulary tier, appeals, and cash-pay options for low-dose naltrexone (LDN) in 2025.
Does Humana Cover Low-Dose Naltrexone?
A guide to Humana's coverage policies, prior authorization requirements, formulary status, and appeal pathways for low-dose naltrexone (LDN) in 2024.
Does Kaiser Permanente Cover Low-Dose Naltrexone?
A detailed guide to Kaiser Permanente's coverage policy, formulary status, prior-authorization requirements, step-therapy rules, and appeal process for low-dose naltrexone (LDN), with cash-pay alternatives and clinical evidence.
Does State Medicaid Cover Low-Dose Naltrexone? A State-by-State Guide
Learn whether your state Medicaid program covers low-dose naltrexone (LDN), how to manage prior authorization, formulary tiers, step therapy rules, and the fair-hearing appeal process.
Does TRICARE Cover Low-Dose Naltrexone?
A guide covering TRICARE formulary status, prior-authorization criteria, step-therapy requirements, appeal pathways, and out-of-pocket costs for low-dose naltrexone (LDN).
Does UnitedHealthcare Cover Low-Dose Naltrexone?
A clinical and insurance guide to UnitedHealthcare coverage for low-dose naltrexone (LDN), including formulary tier, prior authorization criteria, step therapy requirements, appeals, and cash-pay alternatives.
How to Get Low-Dose Naltrexone in Arizona
A guide to obtaining a low-dose naltrexone (LDN) prescription in Arizona, covering telehealth options, compounding pharmacies, required labs, and dosing, with primary-source citations throughout.
How to Get Low-Dose Naltrexone in Delaware
A guide to obtaining a low-dose naltrexone (LDN) prescription in Delaware, covering telehealth access, compounding pharmacies, lab requirements, and Delaware Medicaid prior authorization.
How to Get Low-Dose Naltrexone in District of Columbia
A step-by-step guide to getting a low-dose naltrexone (LDN) prescription in Washington, DC, including telehealth options, compounding pharmacies, labs, insurance, and DC Medicaid prior authorization.
How to Get Low-Dose Naltrexone in Kentucky
A complete guide to obtaining a low-dose naltrexone (LDN) prescription in Kentucky, including telehealth options, compounding pharmacies, costs, and prescriber requirements.
How to Get Low-Dose Naltrexone in Montana
A step-by-step guide to obtaining a low-dose naltrexone (LDN) prescription in Montana, including telehealth options, compounding pharmacies, labs, and cost.
How to Get Low-Dose Naltrexone in Nebraska
A step-by-step guide to obtaining a low-dose naltrexone (LDN) prescription in Nebraska, including telehealth options, compounding pharmacies, costs, and what labs your provider may order first.
How to Get Low-Dose Naltrexone in Virginia
A guide to obtaining a low-dose naltrexone (LDN) prescription in Virginia, covering telehealth options, compounding pharmacy requirements, labs, dosing, and insurance coverage.
Low-Dose Naltrexone (LDN) Dosing for Adults 30, 49: Start Low, Titrate Slow
Evidence-based guide to low-dose naltrexone dosing in adults aged 30, 49, covering initiation, titration, timing, and clinical considerations for off-label use in fibromyalgia, autoimmune conditions, and chronic inflammation.
Low-Dose Naltrexone (LDN) Dosing for Young Adults (18 to 29)
Evidence-based guide to low-dose naltrexone dosing in young adults aged 18 to 29, covering titration schedules, fertility considerations, and clinical monitoring.
Low-Dose Naltrexone Access: A Seven-State Verification Guide
How to verify low-dose naltrexone access in Arizona, Delaware, DC, Kentucky, Montana, Nebraska, and Virginia without relying on stale price, coverage, telehealth, or compounding claims.
Low-Dose Naltrexone After Bariatric Surgery: What You Need to Know
A clinician-level guide to using compounded low-dose naltrexone (LDN) after bariatric surgery, covering altered pharmacokinetics, dosing strategies, safety data, and current clinical evidence.
Low-Dose Naltrexone and Cognitive Function: What the Evidence Actually Shows
An evidence-based breakdown of how low-dose naltrexone (LDN) affects cognitive function, brain fog, neuroinflammation, and mental clarity, including trial data, mechanisms, dosing, and clinical context.
Low-Dose Naltrexone and Liver Function: What the Evidence Actually Shows
A guide to how low-dose naltrexone (LDN) affects liver enzymes and hepatic safety, covering clinical trial data, FDA labeling, monitoring protocols, and who should avoid LDN entirely.
Low-Dose Naltrexone and Sleep Architecture: What the Evidence Actually Shows
Does low-dose naltrexone change REM or deep sleep? A source-grounded review of the human evidence, vivid dreams, insomnia, timing, opioid interactions, and evidence gaps.
Low-Dose Naltrexone Bone Health and Density Impact
An evidence-based look at how low-dose naltrexone (LDN) affects bone density, osteoclast activity, and fracture risk, with primary-literature citations throughout.
Low-Dose Naltrexone Cardiovascular Impact: Long-Term Evidence and Clinical Guidance
A comprehensive analysis of low-dose naltrexone (LDN) and its long-term cardiovascular effects, covering mechanistic data, clinical trials, safety signals, and prescribing guidance for telehealth clinicians.
Low-Dose Naltrexone Cost vs. Alternatives: A Clinical and Financial Comparison
Low-dose naltrexone (LDN) costs $30-$60/month from compounding pharmacies. Compare LDN pricing, mechanism, and evidence against pregabalin, hydroxychloroquine, and biologics for fibromyalgia and autoimmune conditions.
Low-Dose Naltrexone Dosing for Older Adults (50-64): Evidence-Based Guide
How to dose low-dose naltrexone (LDN) for adults aged 50-64, including titration schedules, polypharmacy considerations, and age-specific clinical evidence.
Low-Dose Naltrexone Dosing in Hepatic Impairment: A Clinical Guide
Evidence-based dosing guidance for low-dose naltrexone (LDN) in patients with hepatic impairment, including mechanism of action, pharmacokinetics, monitoring parameters, and compounding considerations reviewed by HealthRX.com physicians.
Low-Dose Naltrexone Dosing in Renal Impairment
Evidence-based guide to low-dose naltrexone (LDN) dosing adjustments in patients with kidney disease, covering pharmacokinetics, safety data, and clinical monitoring protocols.
Low-Dose Naltrexone During Pregnancy and Lactation: What the Evidence Says
A guide to low-dose naltrexone (LDN) safety during pregnancy and breastfeeding, covering animal data, human case reports, FDA labeling, mechanism of action, and clinical decision-making.
Low-Dose Naltrexone Food & Supplement Interactions
A clinical guide to food and supplement interactions with low-dose naltrexone (LDN), including timing, absorption effects, and what to avoid for optimal efficacy.
Low-Dose Naltrexone for Autoimmune Disease: What the Evidence Actually Shows
A guide to low-dose naltrexone (LDN) for autoimmune conditions, covering mechanisms, clinical trial data, dosing, safety, and who may benefit.
Low-Dose Naltrexone Geriatric (65+) Dosing: What Older Adults and Their Clinicians Need to Know
A guide to compounded low-dose naltrexone dosing in adults aged 65 and older, covering starting doses, renal adjustment, fall risk, drug interactions, and deprescribing considerations.
Low-Dose Naltrexone Geriatric (65+) Safety: What Older Adults Need to Know
A guide to low-dose naltrexone (LDN) safety in adults 65 and older, covering renal dosing, drug interactions, fall risk, and deprescribing considerations.
Low-Dose Naltrexone Hair and Skin Changes: What the Evidence Actually Shows
A guide to how low-dose naltrexone (LDN) affects hair growth, hair loss, skin inflammation, and dermatologic autoimmune conditions, with primary-literature citations and dosing context.
Low-Dose Naltrexone in Special Populations: Transplant, HIV, Cancer, Pregnancy, and Pediatric Considerations
Evidence-based guide to using low-dose naltrexone (LDN) in special populations including transplant recipients, people living with HIV, cancer patients, pregnant individuals, children, and those with hepatic or renal impairment.
Low-Dose Naltrexone Manufacturing, Supply & Shortage History
A clinical guide to how low-dose naltrexone (LDN) is manufactured, its compounding pharmacy supply chain, FDA shortage records, and what patients should know about sourcing reliable LDN.
Low-Dose Naltrexone Mechanism of Action: Full Pathway Explained
How low-dose naltrexone (LDN) works at the molecular level. Opioid receptor blockade, glial modulation, endorphin rebound, and immune regulation explained with PubMed-cited evidence.
Low-Dose Naltrexone Mental Health and Mood Impact
How low-dose naltrexone (LDN), typically 1.5 to 4.5 mg, may affect depression, anxiety, and mood, with an honest read of the trial evidence, mechanisms, dosing considerations, and safety limits.
Low-Dose Naltrexone Missed-Dose Protocol: What to Do and Why It Matters
Evidence-based guidance on what to do when you miss a dose of low-dose naltrexone (LDN), plus a full mechanistic explainer, dosing schedules, and FAQ.
Low-Dose Naltrexone Monitoring for Adults (30 to 49): Lab Schedule, Side Effects, and Follow-Up
A clinical guide to monitoring low-dose naltrexone (LDN) in adults aged 30 to 49, covering baseline labs, liver function tests, follow-up schedules, and dose-titration checkpoints.
Low-Dose Naltrexone Monitoring for Older Adults (50 to 64): A Complete Clinical Guide
A guide to monitoring low-dose naltrexone (LDN) in adults aged 50 to 64, covering lab schedules, drug interactions, polypharmacy risks, and dose titration protocols.
Low-Dose Naltrexone Monitoring Schedule: Labs & Exams Your Prescriber Should Order
A complete monitoring schedule for low-dose naltrexone (LDN), including baseline labs, liver function tests, inflammatory markers, thyroid panels, and follow-up exam timing backed by clinical evidence.
Low-Dose Naltrexone Muscle Preservation Strategies: A Clinical Deep-Dive
How low-dose naltrexone (LDN) may support muscle preservation through glial modulation, cytokine reduction, and IGF-1 pathway effects. MD/PharmD-level review with primary literature, dosing guidance, and a decision framework.
Low-Dose Naltrexone Off-Label Uses: Evidence Levels for Every Indication
A breakdown of every major off-label use of low-dose naltrexone (LDN), graded by evidence level, with doses, trial data, and clinical context.
Low-Dose Naltrexone Overdose & Accidental Excess Dose: What to Do and What to Expect
Clinical guide to managing low-dose naltrexone (LDN) overdose and accidental excess doses, including symptoms, timelines, opioid receptor blockade duration, and when to seek emergency care.
Low-Dose Naltrexone Patent Status and Generic Timeline
A clinical review of naltrexone's patent history, current compounding status, FDA-approved formulations, and the regulatory path for a dedicated low-dose naltrexone product.
Low-Dose Naltrexone Pharmacogenomics: How Genetic Variability Shapes LDN Response
Why some patients respond to low-dose naltrexone and others don't. OPRM1, CYP2D6, and other gene variants that influence LDN metabolism, receptor binding, and clinical outcomes.
Low-Dose Naltrexone Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion
A clinical review of low-dose naltrexone (LDN) pharmacokinetics covering ADME, the role of 6-beta-naltrexol, transient opioid receptor blockade, and how compounded 1 to 4.5 mg dosing differs from standard 50 mg naltrexone.
Low-Dose Naltrexone Pre-Surgery Hold Window: What Clinicians and Patients Need to Know
How long before surgery should you stop low-dose naltrexone? This MD/PharmD-level guide covers the evidence-based hold window, opioid-antagonism pharmacokinetics, anesthesia risks, and restart timing after your procedure.
Low-Dose Naltrexone Real-World Evidence: What Registries and Observational Data Actually Show
A clinical review of real-world evidence for low-dose naltrexone (LDN), including national prescription registries, observational cohorts, and patient-reported outcomes across fibromyalgia, autoimmune, and inflammatory conditions.
Low-Dose Naltrexone Regulatory Status: US, EU, Canada, and UK
A clinician-level breakdown of how low-dose naltrexone (LDN) is regulated in the United States, European Union, Canada, and United Kingdom, covering compounding rules, prescribing authority, and what that means for patients in 2025.
Low-Dose Naltrexone Safety for Adults (30 to 49): Side Effects, Risks, and What the Evidence Shows
A clinical review of low-dose naltrexone (LDN) safety in adults aged 30 to 49, covering side effects, drug interactions, liver concerns, and trial data.
Low-Dose Naltrexone Safety for Young Adults (Ages 18 to 29): What the Evidence Actually Shows
A guide to low-dose naltrexone (LDN) safety in adults aged 18 to 29, covering dosing, side effects, fertility, drug interactions, and the current trial evidence.
Low-Dose Naltrexone Safety in Older Adults (50 to 64): What the Evidence Shows
A clinical review of low-dose naltrexone (LDN) safety for adults aged 50 to 64, covering side effects, drug interactions, dosing, and monitoring considerations for this age group.
Low-Dose Naltrexone Safety Signals & FDA Actions
A clinician-grade review of low-dose naltrexone (LDN) safety signals, FDA regulatory actions, compounding pharmacy oversight, and adverse-event data from published trials and FAERS reports.
Low-Dose Naltrexone Seasonal Use Considerations
A clinician-level guide to adjusting low-dose naltrexone (LDN) dosing, timing, and monitoring across seasons, covering winter immune shifts, summer heat effects, and condition-specific seasonal flare patterns.
Low-Dose Naltrexone Self-Injection Technique: Is Injectable LDN a Real Option?
Low-dose naltrexone (LDN) is dispensed as an oral capsule or liquid, not an injectable. Learn how LDN actually works, its mechanism of action via TLR4 and opioid-receptor modulation, and the correct way to take compounded LDN at home.
Low-Dose Naltrexone Storage, Stability & Shelf Life
How to store compounded low-dose naltrexone (LDN), what affects its shelf life, and evidence-based stability data for capsules, liquids, and transdermal formulations.
Low-Dose Naltrexone Switching Protocols: How to Transition From or To Other Drugs in Class
A guide to switching low-dose naltrexone (LDN) from or to other opioid-antagonist and opioid-agonist medications, covering mechanism, timing risk, washout windows, and compounding considerations, with an emphasis on where evidence is solid and where it is not.
Low-Dose Naltrexone Young Adult (18-29) Monitoring
Evidence-based monitoring guide for young adults aged 18-29 taking low-dose naltrexone (LDN). Covers lab schedules, liver function, fertility considerations, and when to adjust dosing.
Low-Dose Naltrexone: Appetite & Cravings Changes Explained
A guide to how low-dose naltrexone (LDN) affects appetite, food cravings, and body weight, with primary-literature citations, dosing context, and practical guidance.
Showing the first 60 matches among the loaded articles. Use the page links below to browse the complete library.